News story

Latest topics referred to NICE: December 2012

This news article was published under the 2010 to 2015 Conservative and Liberal Democrat coalition government

Ministers agreed to refer the following topics to NICE in December, to begin the process of developing guidance for each topic.

Department of Health ministers agreed to refer the following topics to the National Institute for Health and Clinical Excellence** **(NICE) in December, to begin the process of developing guidance for each topic.

Technology appraisals

The following technology appraisals have been referred to NICE.

  • To appraise the clinical and cost effectiveness of afatinib for the treatment of epidermal growth factor receptor mutation positive locally advanced or metastatic non-small cell lung cancer.
  • To appraise the clinical and cost effectiveness of aflibercept within its licensed indication for the treatment of visual impairment due to macular oedema caused by central retinal vein occlusion.
  • To appraise the clinical and cost effectiveness of alemtuzumab within its licensed indication for the treatment of relapsing-remitting multiple sclerosis.
  • To appraise the clinical and cost effectiveness of dimethyl fumarate within its licensed indication for the treatment of relapsing-remitting multiple sclerosis.
  • To appraise the clinical and cost effectiveness of laquinimod within its licensed indication for the treatment of relapsing-remitting multiple sclerosis.
  • To appraise the clinical and cost effectiveness of teriflunomide within its licensed indication for the treatment of relapsing forms of multiple sclerosis.
  • To appraise the clinical and cost effectiveness of dabrafenib within its licensed indication for the treatment of unresectable, advanced or metastatic BRAFV600 mutation-positive melanoma.
  • To appraise the clinical and cost effectiveness of radium-223 dichloride within its licensed indication for the treatment castration-resistant prostate cancer with bone metastases.
  • To appraise the clinical and cost effectiveness of sipuleucel-T within its licensed indication for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer.
  • To appraise the clinical and cost effectiveness of ustekinumab within its licensed indication for the treatment of active and progressive psoriatic arthritis.

Read about NICE technology appraisals on the NICE website.

About NICE referrals

NICE is an independent organisation responsible for providing national guidance on promoting good health and preventing and treating ill health.

Department of Health ministers refer topics to NICE and NICE schedules these topics into its work programme, to begin the process of developing guidance for each topic.

Depending on the type of guidance and its complexity, this can take between 6 months and 2 years.

NICE guidance includes technology appraisals, clinical guidelines, public health guidelines and quality standards.

Find out more about NICE guidance on the NICE website.